About
Pulmonx Corporation is a global medical technology company dedicated to innovative treatments for obstructive lung diseases, particularly emphysema. With headquarters in Redwood City, California, and Neuchâtel, Switzerland, the company is renowned for its Zephyr Endobronchial Valve. This minimally invasive, implantable device is designed to reduce lung hyperinflation in patients with severe emphysema, offering a bronchoscopic lung volume reduction option without the need for surgery. In addition to the Zephyr Valve, Pulmonx provides StratX Lung Analysis Reports, a cloud-based service that delivers detailed insights on emphysema destruction and lung volume. This helps physicians identify the best treatment targets for the Zephyr Valve. The company has also expanded its portfolio through the acquisition of the AeriSeal System from Aeris Therapeutics. Pulmonx is committed to enhancing patient care and quality of life by working closely with pulmonologists and healthcare providers.
Technologies
Keywords
Company Information
-
Employees 300
-
Founded 1995
-
Annual Revenue $83789000
-
Total Funding $368000000
Location
700 Chesapeake Dr, Redwood City, California, United States, 94063